This post was originally published on this site
BRUSSELS (Reuters) – The EU’s executive Commission approved Illumina (NASDAQ:ILMN)’s plan to unwind its completed acquisition of cancer diagnostic test maker Grail, it said in a statement on Friday.
The U.S. gene sequencing company Illumina had announced late last year to divest Grail, after the companies battled both U.S. and European antitrust enforcers for more than two years and faced fierce opposition from activist investor Carl Icahn.
